We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TTD Expands Pharma Reach: Can New Healthcare Integrations Drive Growth
Read MoreHide Full Article
Key Takeaways
TTD expands healthcare ad capabilities through enhanced Veeva Crossix and IQVIA integrations.
Crossix and IQVIA add granular measurement, including Audience Quality and NBRx metrics.
TTD's multi-provider healthcare decisioning can extend NPI reach while improving campaign efficiency.
The Trade Desk (TTD - Free Report) is expanding its healthcare advertising capabilities through enhanced integrations with Veeva Crossix and IQVIA Digital . The move gives pharmaceutical advertisers access to more granular campaign measurement and enables them to use healthcare-specific insights directly in media optimization and decision-making.
Pharmaceutical advertisers require sophisticated measurement because campaign success can extend well beyond conventional digital advertising metrics. TTD’s expanded integrations are designed to connect media exposure with more specific healthcare outcomes and enable advertisers to act on those insights while campaigns are still running. Crossix enables optimization toward Audience Quality and cost per target reach, with NBRx metrics and weighted KPIs expected in the fourth quarter. IQVIA will also add more granular Audience Quality measurement by site, geography and device type, along with NBRx measurement.
The latest integrations align with TTD’s broader effort to expand its presence in specialized advertising verticals and to strengthen its data and decisioning capabilities. Its support for multi-provider healthcare professional decisioning further expands this opportunity. This capability enables advertisers to extend NPI reach across multiple providers, potentially increasing campaign scale while improving efficiency. By combining AI-powered media decisioning with independent healthcare measurement providers, TTD is positioning its platform as a more comprehensive solution for pharmaceutical advertisers.
However, the opportunity will depend on adoption. The benefits of these capabilities ultimately need to translate into increased spending, stronger advertiser retention and greater campaign activity on TTD’s platform. Competition across advertising technology remains intense, with other platforms such as Magnite (MGNI - Free Report) and PubMatic, Inc. (PUBM - Free Report) also investing in AI-powered optimization, data integration and vertical-specific solutions.
Intense Competition Impeding TTD’s Opportunity
Magnite’s growth is driven by strong CTV and DV+ demand. It is seeing broader adoption of programmatic advertising, particularly among premium accounts, while international expansion is providing another growth driver as global streamers rely on programmatic channels to reach new markets. Recently, MGNI announced the launch of its first agentic campaign in EMEA with trading desk Amnet France, highlighting how agentic buying can improve the performance and efficiency of premium CTV campaigns. Magnite also expanded partnerships with major global brands, including Walmart, Samsung, Roku, Viasat, AMC and Dentsu, strengthening its CTV and omnichannel capabilities through automated buying, data-driven targeting and broader programmatic access.
PubMatic'sdisciplined investments have diversified its business, with CTV, mobile app and emerging revenues. In the second quarter, CTV, mobile app and emerging streams accounted for about 60% of revenue and grew nearly 40% year over year. CTV revenue rose 13%, led by 25% growth in the Americas, while mobile app revenue jumped more than 40%, driven by mediation integrations, product innovation and a growing global publisher base. Direct buying on Activate more than doubled globally year over year. In June, PUBM launched its first agentic advertising campaign in Spain with Havas and Movistar, marking a key step in European programmatic CTV adoption.
TTD’s Price Performance, Valuation and Estimates
Shares of TTD have declined 67% in the past year against the Zacks Internet Services industry and S&P 500 composites’ rise of 32.8% and 15.9%, respectively.
Image Source: Zacks Investment Research
From a valuation standpoint, TTD trades at a forward price-to-earnings of 31.71X, higher than the industry’s average of 20.68X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for TTD’s earnings has been revised downward over the past 60 days.
View the Zacks #1 Rank List
Image: Bigstock
TTD Expands Pharma Reach: Can New Healthcare Integrations Drive Growth
Key Takeaways
The Trade Desk (TTD - Free Report) is expanding its healthcare advertising capabilities through enhanced integrations with Veeva Crossix and IQVIA Digital . The move gives pharmaceutical advertisers access to more granular campaign measurement and enables them to use healthcare-specific insights directly in media optimization and decision-making.
Pharmaceutical advertisers require sophisticated measurement because campaign success can extend well beyond conventional digital advertising metrics. TTD’s expanded integrations are designed to connect media exposure with more specific healthcare outcomes and enable advertisers to act on those insights while campaigns are still running. Crossix enables optimization toward Audience Quality and cost per target reach, with NBRx metrics and weighted KPIs expected in the fourth quarter. IQVIA will also add more granular Audience Quality measurement by site, geography and device type, along with NBRx measurement.
The latest integrations align with TTD’s broader effort to expand its presence in specialized advertising verticals and to strengthen its data and decisioning capabilities. Its support for multi-provider healthcare professional decisioning further expands this opportunity. This capability enables advertisers to extend NPI reach across multiple providers, potentially increasing campaign scale while improving efficiency. By combining AI-powered media decisioning with independent healthcare measurement providers, TTD is positioning its platform as a more comprehensive solution for pharmaceutical advertisers.
However, the opportunity will depend on adoption. The benefits of these capabilities ultimately need to translate into increased spending, stronger advertiser retention and greater campaign activity on TTD’s platform. Competition across advertising technology remains intense, with other platforms such as Magnite (MGNI - Free Report) and PubMatic, Inc. (PUBM - Free Report) also investing in AI-powered optimization, data integration and vertical-specific solutions.
Intense Competition Impeding TTD’s Opportunity
Magnite’s growth is driven by strong CTV and DV+ demand. It is seeing broader adoption of programmatic advertising, particularly among premium accounts, while international expansion is providing another growth driver as global streamers rely on programmatic channels to reach new markets. Recently, MGNI announced the launch of its first agentic campaign in EMEA with trading desk Amnet France, highlighting how agentic buying can improve the performance and efficiency of premium CTV campaigns. Magnite also expanded partnerships with major global brands, including Walmart, Samsung, Roku, Viasat, AMC and Dentsu, strengthening its CTV and omnichannel capabilities through automated buying, data-driven targeting and broader programmatic access.
PubMatic's disciplined investments have diversified its business, with CTV, mobile app and emerging revenues. In the second quarter, CTV, mobile app and emerging streams accounted for about 60% of revenue and grew nearly 40% year over year. CTV revenue rose 13%, led by 25% growth in the Americas, while mobile app revenue jumped more than 40%, driven by mediation integrations, product innovation and a growing global publisher base. Direct buying on Activate more than doubled globally year over year. In June, PUBM launched its first agentic advertising campaign in Spain with Havas and Movistar, marking a key step in European programmatic CTV adoption.
TTD’s Price Performance, Valuation and Estimates
Shares of TTD have declined 67% in the past year against the Zacks Internet Services industry and S&P 500 composites’ rise of 32.8% and 15.9%, respectively.
Image Source: Zacks Investment Research
From a valuation standpoint, TTD trades at a forward price-to-earnings of 31.71X, higher than the industry’s average of 20.68X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for TTD’s earnings has been revised downward over the past 60 days.
Image Source: Zacks Investment Research
TTD currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.